目的 评价B超引导下核心针活检术(CNB)对不可触及的乳腺病变(NPBL)的诊断价值。方法 采用18G Tru-cut针结合活检枪对88例患者的96个NPBL行B超引导下CNB,并与切除活检病理结果比较。结果 NPBL大小4~23mm(平均13.1mm)。在CNB中,86个为良性,2个为可疑恶性,6个为恶性,2个取材不良。在切除活检中9个为恶性,87个为良性。CNB可疑恶变的2个NPBL均为恶性,1个恶性NPBL误诊为乳腺腺病,取材不良的2个NPBL均为良性。本组NPBL中恶性病变占9.38%(9/96),B超引导下CNB对NPBL的良恶性诊断正确率为98.94%(93/94),诊断乳腺癌的敏感性为88.89%(8/9),特异性为100%(8/8),良性病变的病理诊断符合率为97.70%(85/87),取材不良为2.08%(2/96)。结论 B超引导下CNB对NPBL的诊断具有较高的敏感性和特异性,结果准确可靠。
目的:评价免疫印迹法检测胰岛自身抗体(GAD-A、ICA、IAA)与酶联免疫法测ICA、GAD-A放射免疫法测IAA结果的一致性。方法:采用免疫印迹法测定81例糖尿病患者胰岛自身抗体,将结果与酶联免疫法测定的GAD-A、ICA,放射免疫法测定IAA结果进行比较。结果:免疫印迹法阳性检出率为:GAD-A 51.8%,ICA 18.5%,IAA 27.1%;酶联免疫法(GAD-A、ICA)、放射免疫法(IAA)阳性检出率:GAD-A 32.1%,ICA 34.5%,IAA 30.8%;上述两组结果进行比较,两组相比ICA和GAD-A有统计学差异(Plt;0.05),IAA无统计学差异。两组结果一致率比较:GAD-A 50.6%,ICA 64.2%,IAA 69.1%。结论:与临床常用酶联免疫法检测GAD-A、ICA,放射免疫法检测IAA比较,免疫印迹法和酶联免疫法在ICA及GAD-A阳性检出率上的差异有显著性,和放射免疫法在IAA阳性检出率上差异无显著性。
Cancer immunotherapy refers to the therapeutic effect of controlling or eliminating tumor cells by interfering with the immune system to restore the anti-tumor immune response. Immune checkpoint inhibitor therapy that blocks programmed death -1/programmed cell death ligand-1/cytotoxic T lymphocyte-associated antigen 4 is one of the most commonly used tumor immunotherapies, with good efficacy and wide application. These drugs cause immune-related ocular complications such as uveitis, autoimmune retinopathy, and scleritis, which represent a new etiology of ocular inflammation. The ophthalmologist's grasp of the clinical characteristics of these diseases is helpful for timely diagnosis. At the same time, the ophthalmologist will work closely with the oncologist to make a comprehensive judgment based on the patient's primary tumor, survival prognosis, severity of adverse reactions related to ocular immunotherapy, and visual prognosis, and develop suitable therapeutic strategie, thereby saving the patients' vision and improving the quality of life.
Objective To detect the expression and clinical significance of POLD1 gene in non-small cell lung cancer (NSCLC) via bioinformatics method. Methods The expression difference of POLD1 in NSCLC tissue and normal lung tissue was investigated by TIMER database. UALCAN database was used to further verify different expression of POLD1 as well as the relationship between POLD1 expression and clinicopathological characteristics of NSCLC. The correlation between POLD1 gene and prognosis of NSCLC patients was detected by GEPIA and TIMER database. cBioPortal database was used to analyze frequencies of POLD1 gene mutation. POLD1-related protein-protein interaction network was constructed by STRING database. The relationship between POLD1 and immune infiltration was based on TISIDB database. Results The expression of POLD1 gene in lung adenocarcinoma and lung squamous cell carcinoma was significantly higher than that in normal lung tissue. In lung adenocarcinoma, patients with lower POLD1 level showed better prognosis. 1.2% of lung adenocarcinoma patients and 1.8% of lung squamous cell carcinoma patients carried mutated POLD1 gene, mainly missense mutations. POLD1 may interact with POLD2, POLD3, POLD4, POLE, RPA1, PCNA, MSH6, MSH2 and FEN1. The biological processes include DNA replication, mismatch repair, etc. Besides, the expression of POLD1 in NSCLC was correlated with the number of different immune cells. Conclusions The POLD1 gene is highly expressed in NSCLC patients, and negatively related with survival prognosis in patients of lung adenocarcinoma. POLD1 gene may be a potential diagnostic target and prognostic marker in NSCLC.
To standardize and improve the reporting quality of digital health implementation research, the Geneva Digital Health Hub has developed the guidelines and checklist for reporting digital health implementations (iCHECK-DH). This paper introduces the background of iCHECK-DH and based on practical application experiences, emphasizes the importance of interdisciplinary collaboration. It focuses on economic cost-effectiveness and local policy guidance in the clinical implementation of digital health technologies. This will provide valuable insights for Chinese scholars when writing implementation reports on digital health technologies.